- Home
- PLSM vs CRIS Comparison
PLSM vs CRIS Comparison
Compare PLSM & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSM | CRIS |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 20.6M |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PLSM | CRIS |
|---|---|---|
| Price | $2.57 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 38.5K | ★ 281.1K |
| Earning Date | 03-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $2.53 | $0.18 |
| 52 Week High | $12.97 | $6.74 |
Technical Indicators
Market Signals| Indicator | PLSM | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 27.47 |
| Support Level | N/A | $0.90 |
| Resistance Level | $3.82 | $5.55 |
| Average True Range (ATR) | 0.28 | 0.30 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 12.37 | 4.82 |
Price Performance
Historical ComparisonAbout PLSM Pulsenmore Ltd. Ordinary Shares
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.